Humanization of an anti-mucin antibody for breast and ovarian cancer therapy

Adv Exp Med Biol. 1994:353:61-82. doi: 10.1007/978-1-4615-2443-4_8.

Abstract

Antibody-drug conjugates utilize the targetting potential of antibodies to improve the potential of cytostatic or cytocidal drugs. One such murine monoclonal antibody, CTM01 (mCTM01), which recognizes an epitope on breast epithelial mucin, has potential for the treatment of breast and ovarian cancers. We examine in this paper the comparative properties of mCTM01 against a number of other anti-mucin antibodies. We then describe the humanization and high level re-expression of humanized CTM01 (hCTM01), a process designed to avoid the immune response to administered murine antibodies in human patients and to produce sufficient material for clinical studies. We show that the humanized form has properties superior to mCTM01 in terms of binding affinity to antigen presented on tumour cells.

Publication types

  • Comparative Study

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal / chemistry*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibody Affinity
  • Antigens, Neoplasm / immunology*
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / therapy
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunotherapy*
  • Membrane Glycoproteins / immunology*
  • Mice
  • Minisatellite Repeats
  • Molecular Sequence Data
  • Mucin-1
  • Mucins / immunology*
  • Neoplasm Proteins / immunology
  • Ovarian Neoplasms / immunology*
  • Ovarian Neoplasms / therapy
  • Peptide Fragments / immunology
  • Protein Engineering*
  • Recombinant Fusion Proteins / chemistry*
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Membrane Glycoproteins
  • Mucin-1
  • Mucins
  • Neoplasm Proteins
  • Peptide Fragments
  • Recombinant Fusion Proteins